CORRESP

eFFECTOR Therapeutics, Inc.

142 North Cedros Avenue, Suite B

Solana Beach, CA 92075

September 7, 2022

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

  Re:

eFFECTOR Therapeutics, Inc.

Registration Statement on Form S-3

File No. 333-267221

To the addressees set forth above:

Pursuant to Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, the undersigned, on behalf of eFFECTOR Therapeutics, Inc., respectfully requests that the effective date of the Registration Statement on Form S-3 referred to above be accelerated so that it will become effective at 4:00 P.M. Eastern Time on September 9, 2022, or as soon as practicable thereafter.

If you have any questions or require additional information, please contact Matthew T. Bush, Esq. of Latham & Watkins LLP at (858) 523-3962. Thank you for your assistance and cooperation in this matter.

 

Very truly yours,

 

eFFECTOR THERAPEUTICS, INC.

By:   /s/ Michael Byrnes
  Michael Byrnes
  Chief Financial Officer

 

cc:

Cheston J. Larson, Latham & Watkins LLP

Matthew T. Bush, Latham & Watkins LLP